Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
Phase 4
Completed
- Conditions
- Glaucoma
- Registration Number
- NCT00468988
- Lead Sponsor
- Alcon Research
- Brief Summary
Compare the effect of Xalatan with benzalkonium chloride on the ocular surface to those effects observed with Travatan Z without benzalkonium chloride after a single dose
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma
Exclusion Criteria
- Age
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Tear Break Up Time Day
- Secondary Outcome Measures
Name Time Method Safety Onset
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which latanoprost and travoprost modulate intraocular pressure in glaucoma patients?
How does benzalkonium chloride in Xalatan impact ocular surface biomarkers compared to preservative-free Travatan Z in short-term studies?
What evidence supports the comparative effectiveness of prostaglandin analogs with and without preservatives in managing ocular surface disease in glaucoma?
What adverse events are associated with benzalkonium chloride-preserved versus non-preserved prostaglandin eye drops in short-term use for glaucoma?
Are there combination therapies involving latanoprost or travoprost that improve efficacy while reducing ocular surface toxicity in glaucoma treatment?
Trial Locations
- Locations (1)
Orlando
🇺🇸Orlando, Florida, United States
Orlando🇺🇸Orlando, Florida, United States